1. In patients receiving carotid stenosis treatment, transcarotid artery revascularization was associated with a significantly lower risk of stroke or death compared to transfemoral carotid artery stenting.

Evidence Rating Level:2 (Good)

Study Rundown: Transfemoral carotid artery stenting has served as an alternative approach to the standard of care, for patients requiring treatment for carotid artery stenosis.  However, the transfemoral approach has been linked with a higher periprocedural stroke risk when compared to the transcarotid approach.  This study examined the risk of stroke or death in patients undergoing treatment for carotid artery stenosis via the transcarotid approach versus the transfemoral approach.  The exploratory propensity score-matched analysis revealed that transfemoral carotid artery stenting was associated with significantly higher risk of stroke or death compared to the transcarotid artery stenting.

Read More: https://www.2minutemedicine.com/transcarotid-artery-revascularization-associated-with-lower-risk-of-stroke-or-death/

Financing to Support Commercial Acceleration of the Tablo® Hemodialysis System, an Enterprise Solution Designed to Reduce the Cost and Complexity of Dialysis

SAN JOSE, Calif., Feb. 4, 2020 /PRNewswire/ -- Outset Medical, a leading medtech innovator delivering first-of-its-kind technology into the growing global dialysis market, today announced a $125 million Series E equity financing round led by D1 Capital Partners. Fidelity Management and Research Company, Partner Fund Management, Perceptive Advisors, funds advised by T. Rowe Price Associates Inc., also are participating in the financing.

Proceeds will be used to support commercial expansion of Outset Medical's Tablo Hemodialysis System across the acute and chronic care markets in the United States. Designed to reduce the cost and complexity of dialysis, Tablo expands how, when, and where dialysis can be provided.

Read More: https://www.prnewswire.com/news-releases/outset-medical-announces-125-million-financing-led-by-d1-capital-partners-300998158.html

Hinge Health, the San Francisco-based startup that offers a digital solution to treat chronic musculoskeletal (MSK) conditions — such as back and joint pain — has closed a $90 million Series C.

The round is led by Bessemer Venture Partners,  with participation from Lead Edge Capital. All of Hinge’s existing institutional investors followed on: Insight Partners (which led the Series B), Atomico (which led the Series A), 11.2 Capital, Quadrille Capital and Heuristic Capital.

Founded in 2015 (and originally based in London), Hinge Health  primarily sells into U.S. employers and health plans, billing itself as a digital healthcare solution for chronic MSK conditions. The platform combines wearable sensors, an app and health coaching to remotely deliver physical therapy and behavioral health.

Read More: https://techcrunch.com/2020/02/04/hinge-health-series-c/